β-Thalassemia: Expert Insights on New Therapies for an Old Disease
  • CME

In this CME-certified, on-demand Webcast of a CCO symposium at ASH 2019, a panel of experts discusses current management of β-thalassemia, the evolving role of biologic therapies changing the course of this disease, and the promise of gene therapy for a cure, including guidance on a series of patient cases and panel question and answer session.
Maria Domenica Cappellini, MD
Janet L. Kwiatkowski, MD, MSCE
Sujit Sheth, MD
Physicians: maximum of 3.0 AMA PRA Category 1 Credits
Released: January 15, 2020 Expiration: January 14, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the medical need for novel therapeutic strategies for the management of β-thalassemia
  • Describe the safety and efficacy evidence for novel approaches to reducing transfusion dependence through the use of erythroid maturation agents
  • Explain the mechanism of action of gene therapy as a curative approach to β-thalassemia
  • Examine key efficacy and safety data on emerging gene therapy strategies and their potential role in the management of patients with β-thalassemia
  • Identify patients with β-thalassemia who are candidates for ongoing clinical trials

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Maria Domenica Cappellini, MD

Professor of Internal Medicine
Chief, Internal Medicine Unit
Internal Medicine Department
University of Milan-Fondazione IRCCS Ca' Granda Policlinico Hospital
Milan, Italy

Maria Domenica Capellini, MD, has disclosed that she is a member of advisory boards for Bluebird Bio, Celgene, CRISPR Therapeutics, Ionis, Novartis, and Sanofi/Genzyme.
Janet L. Kwiatkowski, MD, MSCE

Professor of Pediatrics
Director of Thalassemia Program

Division of Hematology
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Janet L. Kwiatkowski, MD, MSCE, has disclosed that she has served on advisory boards for Agios, Bluebird Bio, and Celgene; has received consulting fees from Silence Therapeutics; and has received funds for research support from ApoPharma, Bluebird Bio, Novartis, and Terumo BCT.
Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Sujit Sheth, MD, has disclosed that he has received consulting fees from Acceleron and Celgene and funds for research support from ApoPharma, Celgene, CRISPR/Vertex, La Jolla, Novartis, and Terumo.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME/CE services from Harmony Biosciences, Saluda Medical, and Shionogi.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologists and other clinicians involved in the management of patients with β-Thalassemia

Goal

The goal of this activity is to improve participants’ knowledge of and competence in using novel curative and noncurative therapeutic options for patients with β-thalassemia.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 3.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 15, 2020, through January 14, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slides with expert recommendations on the integration of oncology biosimilars into clinical practice from Clinical Care Options.

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP Released: April 20, 2020

Downloadable slides with expert recommendations on the management of patients with acute and chronic graft versus host disease (GVHD) from Clinical Care Options.

Corey S. Cutler, MD, MPH, FRCPC Released: April 13, 2020

Clinical Care Options (CCO) downloadable resource guide for the optimal management of patients with graft-vs-host disease (GVHD).

Released: April 10, 2020

Review key data in hematologic malignancies and nonmalignant hematologic disorders from ASH 2019 with these CME-certified expert commentaries from CCO

Hanny Al-Samkari, MD Rami S. Komrokji, MD Sagar Lonial, MD Jeff P. Sharman, MD Sujit Sheth, MD Eunice S. Wang, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 17, 2020 Expired: March 16, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?